Full text is available at the source.
Abstract
Mazdutide, a dual agonist targeting glucagon and GLP-1 receptors, is evaluated for weight reduction in adults with obesity or overweight.
- Mazdutide may provide effective weight loss in adults with obesity or overweight.
- The study investigates doses of mazdutide up to 16 mg.
- Safety and tolerability are key components of the evaluation.
- Participants did not have type 2 diabetes.
Simplified
GLP-1 Therapies